HeartFlow, Inc. (HTFL) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 470.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.42
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 626
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.27
• Shares Outstanding: 85,158,720
• 10 Day Avg. Volume: 634,012
• 30 Day Avg. Volume: 470,951
• PEG Ratio: 0.81
• Price to Book (P/B): -2.11
• Price to Sales (P/S): 14.41
• P/FCF Ratio: -24.71
• Enterprise Value/Market Cap: 10.00T>
• Enterprise Value/Revenue: 20.02
• Enterprise Value/Gross Profit: 26.43
• Enterprise Value/Ebitda: -53.61
• 1Y Price Target: $38.60
• Price Target Upside: 28.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.95
• Revenue Forecast (FY): $165.86M

• Rating: 39 Underperform
• Price Target: $29.00 ▼(-3.81% Downside)

HeartFlow, Inc. receives a low overall stock score due to significant financial challenges, including ongoing losses, negative equity, and cash flow issues. The technical analysis indicates a bearish trend with weak momentum, further impacting the score. The absence of valuation metrics highlights the company's struggle to achieve profitability.

Positive Factors

Strong Gross Profit Margin

A robust gross profit margin suggests effective cost control, which can provide a buffer against revenue fluctuations and support long-term profitability.

Innovative Business Model

HeartFlow's innovative approach in non-invasive diagnostics positions it well in the healthcare sector, potentially driving future demand and market expansion.

Strategic Partnerships

Strategic partnerships enhance market reach and service volume, providing a stable revenue stream and potential for growth through expanded network effects.

Negative Factors

Negative Equity

Negative equity highlights financial instability, which can limit access to capital and increase risk, potentially impacting long-term operational viability.

Cash Flow Issues

Negative cash flows suggest ongoing cash burn, which can strain resources and necessitate external financing, affecting long-term sustainability.

Stagnant Revenue Growth

Lack of revenue growth limits the company's ability to scale and improve profitability, posing challenges to achieving sustainable financial performance.

HeartFlow, Inc. Business Overview & Revenue Model

Company Description

HeartFlow, Inc. is a medical technology company focused on transforming cardiovascular care through its innovative imaging solutions. It operates primarily within the healthcare sector, specializing in non-invasive coronary artery disease diagnostics. HeartFlow's core product, the HeartFlow Analysis, utilizes advanced computational fluid dynamics to create a personalized 3D model of a patient's coronary arteries, allowing physicians to assess the impact of blockages and make informed treatment decisions.

How the Company Makes Money

HeartFlow generates revenue primarily through the sale of its HeartFlow Analysis services to hospitals and healthcare providers. The company operates on a fee-for-service model where it charges for each analysis performed. Additionally, HeartFlow has established significant partnerships with various hospitals and healthcare systems, which help to expand its reach and drive volume for its services. The company may also benefit from reimbursement agreements with insurance providers, making its services more accessible to patients and contributing to its earnings.

HeartFlow, Inc. Financial Statement Overview

Summary

HeartFlow, Inc. faces significant financial challenges with ongoing losses, negative equity, and cash flow issues. While the gross profit margin is strong, the lack of revenue growth and negative profitability metrics highlight the need for strategic improvements. The company must address its financial instability to ensure long-term viability.

Income Statement

HeartFlow, Inc. shows a strong gross profit margin of 75.07%, indicating efficient cost management relative to revenue. However, the company faces significant challenges with negative net profit, EBIT, and EBITDA margins, reflecting ongoing losses and operational inefficiencies. Revenue growth is stagnant, which could hinder future profitability improvements.

Balance Sheet

The balance sheet reveals a concerning negative stockholders' equity, indicating potential financial instability. The debt-to-equity ratio is negative due to negative equity, which complicates leverage assessment. Return on equity is positive, but this is misleading due to the negative equity base.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that cash flows are somewhat aligned with net income, albeit negative. The company needs to improve cash generation to support operations.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	126.91M	125.81M	87.17M
Gross Profit	96.13M	94.45M	58.05M
EBITDA	-47.39M	-65.47M	-62.83M
Net Income	-92.40M	-96.43M	-95.66M
Balance Sheet
Total Assets	364.40M	118.70M	185.05M
Cash, Cash Equivalents and Short-Term Investments	291.17M	51.37M	122.77M
Total Debt	21.79M	160.38M	160.60M
Total Liabilities	109.83M	978.19M	962.62M
Stockholders Equity	254.57M	-859.48M	-777.56M
Cash Flow
Free Cash Flow	-46.55M	-73.36M	-82.54M
Operating Cash Flow	-43.43M	-69.00M	-76.43M
Investing Cash Flow	-3.13M	-4.36M	-6.11M
Financing Cash Flow	286.09M	2.24M	169.32M

HeartFlow, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	67 Neutral	$753.57M	37.23	5.87%	0.49%	3.68%	5.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMWL	48 Neutral	$81.57M	―	-38.35%	―	4.33%	50.50%
TDOC	47 Neutral	$1.32B	―	-15.42%	―	-2.37%	77.85%
DH	42 Neutral	$396.10M	-1.05	-47.69%	―	-5.30%	46.01%
HTFL	39 Underperform	―	―	―	―	―	―
BEAT	34 Underperform	$56.61M	-2.37	-792.01%	―	―	4.31%

HeartFlow, Inc. Corporate Events

HeartFlow, Inc. Reports Robust Q3 2025 Revenue Growth

HeartFlow, Inc., a leader in artificial intelligence technology for coronary artery disease, specializes in transforming cardiovascular care through its innovative HeartFlow One platform. The company leverages AI to create 3D models of the heart, offering actionable insights without invasive procedures.

HeartFlow’s Innovative Study on Cardiac Risk in NFL Alumni: A Potential Game-Changer

HeartFlow, Inc. is conducting a clinical study titled ‘Using CTA Measures to Define Cardiac Risk In NFL Alumni.’ The study aims to assess the presence of Coronary Artery Disease (CAD) in retired NFL players using Coronary Computed Tomography Angiography (CCTA). This research is significant as it seeks to understand cardiac risks in a specific population, potentially leading to improved diagnostic and preventive strategies.

HeartFlow’s COMPLETE Study: A New Frontier in Coronary Artery Disease Evaluation

The COMPLETE Study, officially titled ‘Comprehensive Anatomical and Physiological Evaluation of Patients With Stable Coronary Artery Disease,’ aims to evaluate the accuracy of coronary CT angiography in quantifying total atheroma volume, using intravascular ultrasound as a reference. This study is significant as it could enhance diagnostic precision for coronary artery disease, potentially improving patient outcomes.

HeartFlow Releases Investor Presentation at Healthcare Conference

HeartFlow, Inc. has released its Investor Presentation in conjunction with the Morgan Stanley 23rd Annual Global Healthcare Conference. This move is part of the company’s ongoing efforts to provide transparency and updates to its stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (HTFL) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on HeartFlow, Inc. stock, see the HTFL Stock Forecast page.

HeartFlow, Inc. Terminates Credit Agreement with Hayfin

On August 22, 2025, HeartFlow, Inc. prepaid in full all outstanding amounts under a Credit Agreement with Hayfin Services LLP, totaling $61.1 million, and subsequently terminated the agreement without incurring any exit or prepayment fees. This financial maneuver reflects HeartFlow’s strategic move to enhance its financial flexibility and could positively impact its liquidity and capital resources, as previously discussed in its financial filings.